Advanced search
Publication Cover
Cancer Management and Research Volume 14, 2022 - Issue
Submit an article Journal homepage
103
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report

Suyao Li1 Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-2765-3282View further author information
ORCID Icon,
Qing Liu1 Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China;2 Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Mengling Liu1 Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of ChinaView further author information
&
Tianshu Liu1 Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China;2 Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8604-6311View further author information
ORCID Icon
Pages 2927-2932 | Received 06 May 2022, Accepted 10 Aug 2022, Published online: 27 Nov 2023

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. doi:10.3322/caac.21590
  • Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review. JAMA. 2020;324:1980–1991. doi:10.1001/jama.2020.17598
  • Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–556 e525. doi:10.1016/j.cell.2017.09.007
  • Robichaux JP, Elamin YY, Vijayan RSK, et al. Pan-cancer landscape and analysis of erbb2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of t-dm1 activity. Cancer Cell. 2019;36:444–457.e7. doi:10.1016/j.ccell.2019.09.001
  • Cousin S, Khalifa E, Crombe A, et al. Targeting erbb2 mutations in solid tumors: biological and clinical implications. J Hematol Oncol. 2018;11:86. doi:10.1186/s13045-018-0630-4
  • Hyman DM, Piha-Paul SA, Won H, et al. Her kinase inhibition in patients with her2- and her3-mutant cancers. Nature. 2018;554:189–194. doi:10.1038/nature25475
  • Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–475. doi:10.1016/j.eururo.2016.06.020
  • Xu S, Lou F, Wu Y, et al. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Lett. 2016;370:324–331. doi:10.1016/j.canlet.2015.11.005
  • Thompson JC, Yee SS, Troxel AB, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res. 2016;22:5772–5782. doi:10.1158/1078-0432.CCR-16-1231
  • Sashide K, Isobe H, Wakumoto Y, et al. Ca19-9 as a serum marker for poor prognosis in urothelial carcinoma. Urol Int. 2004;72:112–117. doi:10.1159/000075963
  • Kovacs E, Zorn JA, Huang Y, et al. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem. 2015;84:739–764. doi:10.1146/annurev-biochem-060614-034402
  • Gaibar M, Beltran L, Romero-Lorca A, et al. Somatic mutations in her2 and implications for current treatment paradigms in her2-positive breast cancer. J Oncol. 2020;2020:6375956. doi:10.1155/2020/6375956
  • Bose R, Kavuri SM, Searleman AC, et al. Activating her2 mutations in her2 gene amplification negative breast cancer. Cancer Discov. 2013;3:224–237. doi:10.1158/2159-8290.CD-12-0349
  • Kavuri SM, Jain N, Galimi F, et al. Her2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015;5:832–841. doi:10.1158/2159-8290.CD-14-1211
  • Ng PK, Li J, Jeong KJ, et al. Systematic functional annotation of somatic mutations in cancer. Cancer Cell. 2018;33:450–462 e410. doi:10.1016/j.ccell.2018.01.021
  • Cocco E, Lopez S, Santin AD, et al. Prevalence and role of her2 mutations in cancer. Pharmacol Ther. 2019;199:188–196. doi:10.1016/j.pharmthera.2019.03.010
  • Blair HA. Pyrotinib: first global approval. Drugs. 2018;78:1751–1755. doi:10.1007/s40265-018-0997-0
  • Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in her2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, Phase II study. J Clin Oncol. 2019;37:2610–2619. doi:10.1200/JCO.19.00108
  • Gourd E. Pyrotinib versus lapatinib in her2-positive breast cancer. Lancet Oncol. 2019;20:e562. doi:10.1016/S1470-2045(19)30568-6
  • Wang Y, Jiang T, Qin Z, et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol. 2019;30:447–455. doi:10.1093/annonc/mdy542
  • Zhou C, Li X, Wang Q, et al. Pyrotinib in -mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase ii study. J Clin Oncol. 2020;38:2753–2761. doi:10.1200/JCO.20.00297
  • Song Z, Li Y, Chen S, et al. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. BMC Med. 2022;20:42. doi:10.1186/s12916-022-02245-z
  • Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-erbb receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35:3105–3112. doi:10.1200/JCO.2016.69.6179
  • Li Q, Guan X, Chen S, et al. Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in her2-positive metastatic breast cancer patients: a phase i clinical trial. Clin Cancer Re. 2019;25:5212–5220. doi:10.1158/1078-0432.CCR-18-4173

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.